NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
Symbol
NBP on Nasdaq
Shares outstanding
264,351,875
Price per share
$3.97
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
29,690,135
Total reported value
$112,309,052
% of total 13F portfolios
0%
Share change
+20,297,042
Value change
+$77,501,715
Number of holders
42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Everest Medicines Ltd 16% $90,577,645 42,524,716 Everest Medicines Limited 05 Aug 2025
CBC Investment I-Mab Ltd 10% -42% $58,559,227 -$12,947,350 27,492,595 -18% Wei Fu 05 Aug 2025

As of 30 Sep 2025, 42 institutional investors reported holding 29,690,135 shares of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP). This represents 11% of the company’s total 264,351,875 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 3% 7,991,377 0.01% $30,287,319
HHLR ADVISORS, LTD. 2.3% 5,980,568 0% 0.55% $22,606,547
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.3% 3,338,034 0.02% $12,617,769
MORGAN STANLEY 0.84% 2,232,040 +3729% 0% $8,437,112
Ariose Capital Management Ltd 0.64% 1,704,393 +1667% 2.2% $6,442,606
Exome Asset Management LLC 0.54% 1,439,604 3.7% $5,441,703
Siren, L.L.C. 0.44% 1,165,957 0.17% $4,407,317
Candriam S.C.A. 0.43% 1,132,563 0% 0.02% $4,281,088
Woodline Partners LP 0.4% 1,050,000 0.02% $3,969,000
Point72 Hong Kong Ltd 0.21% 561,366 0.1% $2,121,963
SG Americas Securities, LLC 0.18% 463,894 -47% 0.01% $1,754,000
BARCLAYS PLC 0.15% 395,431 +1202% 0% $1,494,729
STATE STREET CORP 0.13% 337,400 0% $1,275,372
UBS Group AG 0.11% 295,078 +60% 0% $1,115,395
GOLDMAN SACHS GROUP INC 0.08% 218,470 +1945% 0% $825,817
Connor, Clark & Lunn Investment Management Ltd. 0.06% 164,064 +490% 0% $620,162
JPMORGAN CHASE & CO 0.06% 150,164 0% $567,620
SUPERSTRING CAPITAL MANAGEMENT LP 0.05% 139,886 0.52% $528,769
BNP PARIBAS FINANCIAL MARKETS 0.05% 119,512 0% 0% $451,755
ALPS ADVISORS INC 0.04% 111,490 0% $421,432
LMR Partners LLP 0.04% 100,000 0% $378,000
DIMENSIONAL FUND ADVISORS LP 0.04% 98,776 +69% 0% $373,373
Point72 Asset Management, L.P. 0.03% 77,348 0% $292,376
XTX Topco Ltd 0.03% 72,104 0.01% $272,553
RENAISSANCE TECHNOLOGIES LLC 0.02% 63,600 -0.16% 0% $240,408

Institutional Holders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 36,481 $145,000 -$1,864,156 $3.97 1
2025 Q3 29,690,135 $112,309,052 +$77,501,715 $3.78 42
2025 Q2 9,395,986 $22,737,366 +$2,030,864 $2.42 32
2025 Q1 8,993,007 $7,408,233 -$2,236,666 $0.82 29
2024 Q4 11,912,678 $10,125,354 -$4,196,499 $0.85 27
2024 Q3 14,193,703 $17,600,522 -$1,644,775 $1.24 27
2024 Q2 15,140,525 $25,329,475 +$4,917,141 $1.67 37
2024 Q1 12,194,479 $22,682,620 -$591,267 $1.86 38
2023 Q4 12,343,395 $23,450,292 -$3,932,021 $1.90 43
2023 Q3 15,251,229 $20,128,696 -$8,412,218 $1.32 46
2023 Q2 18,691,045 $55,880,438 -$6,382,969 $2.99 46
2023 Q1 20,700,388 $71,623,449 -$16,502,335 $3.46 51
2022 Q4 24,863,205 $103,919,915 -$23,835,362 $4.18 63
2022 Q3 30,756,340 $123,319,030 -$78,451,098 $4.01 69
2022 Q2 38,195,150 $430,214,056 -$43,072,457 $11.30 91
2022 Q1 40,274,792 $654,272,172 -$2,809,989 $16.24 112
2021 Q4 39,063,350 $1,843,596,654 +$49,692,681 $47.39 127
2021 Q3 36,035,033 $2,613,664,389 +$445,184,584 $72.49 140
2021 Q2 28,287,880 $2,375,233,906 +$495,487,800 $83.95 133
2021 Q1 23,316,491 $1,130,077,433 +$490,958,954 $48.47 78
2020 Q4 13,056,509 $615,418,000 +$200,018,636 $47.15 63
2020 Q3 9,526,320 $447,661,000 +$236,962,427 $47.03 48
2020 Q2 3,298,968 $97,724,000 -$2,617,263 $29.93 19
2020 Q1 3,439,668 $44,717,000 +$44,717,000 $13.00 15